Subscribe
  
IPQ Inside the global regulatory dialogue

Airport Radiation Screening-Induced Recall Highlights PET Drug GMP Challenges; FDA Releases PET Media Fill Guidance

Oct 31st, 2011

Please Log in to print the full article

The challenge and importance of GMP management of positron emission tomography (PET) drug processes is underscored by FDA in a new guidance released in October on PET media fills and exemplified by a recent recall of a prominent PET generator.

In late July, Bracco Diagnostics initiated a recall of it CardioGen-82 after patients who received diagnostic procedures two to four months earlier set off radiation scanners at US airports.

The patients received more radiation than expected apparently due to a hospital user error and/or an equipment malfunction that caused strontium to be inadvertently released into the preparation.

The rubidium (Rb-82) used in the procedure is collected from the generator column by injecting a solution of saline through the column.  Under normal conditions, only the Rb-82 is released into the solution, while the strontium remains attached to the column.  Strontium has a half-life of 25 days, whereas rubidium-82 has a half-life of 75 seconds.

CardioGen-82 consists of a generator used at clinical sites to produce rubidium-82 chloride injection and is one of a variety of nuclear medicine scans that use radioactive drugs to evaluate the heart.  All units have now been recalled, exacerbating a shortage of the imaging drug that began in January.

[The story continues for subscribers beginning on page 2.  Nonsubscribers can purchase the story for $95 by contacting Wayne Rhodes ([email protected]).  For subscription/license information, click here].

Pages: 1 2

    ©2021 IPQ Publications